For more than 60 years, ANSTO has manufactured a range of nuclear medicines called radiopharmaceuticals, which are used as both diagnostic and therapeutic agents in clinical settings, as well as in medical research.
Follow the journey
It is expected many Australians will benefit from the use of nuclear medicine in their lifetime.
Take a look at how nuclear medicine makes its way from ANSTO's OPAL reactor to medical centres around Australia.
ANSTO delivers thousands of patient doses of Tc-99m to hospitals and nuclear medicine centres in Australia every week
Producing nuclear medicine in Australia
The most widely used radioisotope in nuclear medicine, technetium-99 (Tc-99m), decays from its parent radioisotope molybdenum-99 (Mo-99). Mo-99 is produced in Australia by ANSTO.
Tc-99m emits very small amounts of radiation that can be detected by PET and SPECT gamma cameras. The images provide vital information to doctors on physiological processes in the body and are used to diagnose disease.
Mo-99 is produced in the multipurpose OPAL nuclear reactor, processed at ANSTO’s new Mo-99 Manufacturing Facility and despatched to practitioners in shielded Gentech® Generators manufactured by ANSTO.
ANSTO also produces a diverse range of radiochemicals to support research, industry and the manufacture of radiopharmaceuticals.